Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Volitionrx Ltd (VNRX)

Volitionrx Ltd (VNRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 27,262
  • Shares Outstanding, K 135,565
  • Annual Sales, $ 1,230 K
  • Annual Income, $ -26,970 K
  • EBIT $ -23 M
  • EBITDA $ -22 M
  • 60-Month Beta 1.33
  • Price/Sales 13.66
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.22
  • Most Recent Earnings $-0.04 on 11/13/25
  • Next Earnings Date 03/30/26 [--]
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Options Overview Details

View History
  • Implied Volatility 678.06% (-18.45%)
  • Historical Volatility 92.37%
  • IV Percentile 81%
  • IV Rank 42.55%
  • IV High 1,285.20% on 02/04/26
  • IV Low 228.31% on 11/12/25
  • Expected Move (DTE 23) 1.9720 (1,030.84%)
  • Put/Call Vol Ratio 0.09
  • Today's Volume 76
  • Volume Avg (30-Day) 49
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 3,671
  • Open Int (30-Day) 3,884
  • Expected Range 0.0000 to 2.1633

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.04
  • Number of Estimates 2
  • High Estimate -0.04
  • Low Estimate -0.04
  • Prior Year -0.06
  • Growth Rate Est. (year over year) +33.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.1710 +11.87%
on 03/23/26
0.3029 -36.84%
on 03/18/26
-0.0519 (-21.34%)
since 02/25/26
3-Month
0.1700 +12.53%
on 02/24/26
0.3863 -50.48%
on 01/08/26
-0.0607 (-24.09%)
since 12/24/25
52-Week
0.1700 +12.53%
on 02/24/26
0.9400 -79.65%
on 06/23/25
-0.3616 (-65.40%)
since 03/25/25

Most Recent Stories

More News
VolitionRx Limited Schedules Full Fiscal Year 2025 Earnings Conference Call and Business Update

Conference call to take place on Wednesday, April 1 at 8:30 a.m. U.S Eastern Time

VNRX : 0.1913 (-4.87%)
Volition Announces Detection of Over 95% of Early-Stage Cancers

HENDERSON, Nev. , March 25, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces compelling proof of concept data from a blinded...

VNRX : 0.1913 (-4.87%)
Volition Reports Breakthrough in Liquid Biopsy: Achievement of over 99% Purity in Isolating Cancer DNA

HENDERSON, Nev. , March 18, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, is the first to demonstrate the isolation and analysis...

VNRX : 0.1913 (-4.87%)
Volition Announces First Ever Automated Nu.Q® Vet Cancer Test with Fujifilm Vet Systems

HENDERSON, Nev. , March 6, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces the completion of all validation and verification...

VNRX : 0.1913 (-4.87%)
VolitionRx Highlights Commercial Momentum and Multi-Pillar Execution

HENDERSON, Nev. , Feb. 25, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, is pleased to provide a consolidated update on the significant...

VNRX : 0.1913 (-4.87%)
Volition Announces the Appointment of New Distributor for Nu.Q® Discover

HENDERSON, Nev. , Feb. 10, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces the appointment of Medical & Biological Laboratories...

VNRX : 0.1913 (-4.87%)
VolitionRx Receives Notice of Non-Compliance with NYSE American Continued Listing Standards

HENDERSON, Nev. , Feb. 9, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition" or the "Company"), a multi-national epigenetics company, announced today that on February 6, 2026,...

VNRX : 0.1913 (-4.87%)
Volition Sponsors Symposium at 15th Conference of the European Hidradenitis Suppurativa Foundation

  Showing New Indication for Nu.Q ® NETs 

VNRX : 0.1913 (-4.87%)
VolitionRx Limited Announces the Preparation of Reimbursement Submission for its Nu.Q® Cancer Assays

HENDERSON, Nev. , Jan. 30, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces the preparation of the reimbursement submission...

VNRX : 0.1913 (-4.87%)
Volition Announces Data to Support Use of Nu.Q® NETs in New Indication

Nu.Q® Biomarker Paper Available on MedRXIV

VNRX : 0.1913 (-4.87%)

Business Summary

Volition RX Ltd is a life sciences company engaged in developing a range of blood-based epigenetic cancer diagnostic tests. Its tests are designed to detect the nucleosome patterns that are specific to cancer in the blood, and identify some of the major nucleosome varieties that differ between cancer...

See More

Key Turning Points

3rd Resistance Point 0.2773
2nd Resistance Point 0.2580
1st Resistance Point 0.2246
Last Price 0.1913
1st Support Level 0.1719
2nd Support Level 0.1526
3rd Support Level 0.1192

See More

52-Week High 0.9400
Fibonacci 61.8% 0.6459
Fibonacci 50% 0.5550
Fibonacci 38.2% 0.4641
Last Price 0.1913
52-Week Low 0.1700

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.